NCT01268293

A Study of E7080 in Subjects With Solid Tumor

A Phase 1 Study of E7080 in Subjects With Solid Tumor

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Eisai Co., Ltd. · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the tolerability and safety of E7080 up to 24 mg when administered orally on a once daily continuous dose schedule in cycles (4 weeks as 1 cycle) in subjects with solid tumors

Conditions

• Cancer

Interventions

Type	Name	Description
DRUG	E7080	This arm will be a dose-escalation evaluation of 9-18 subjects to investigate the tolerability and safety of E7080 up to 24 mg when administered orally on a once daily continuous dose schedule in cycles (4 weeks as 1 cycle). Administration of the study drug can continue until subjects meet discontinuation criteria such as disease progression, intolerable toxicity, and withdrawal of study consent.

Timeline

• Start date: 2011-02-01
• Primary completion: 2011-12-01
• Completion: 2013-04-01
• First posted: 2010-12-30
• Last updated: 2023-06-22
• Results posted: 2015-03-06

Locations

1 site across 1 country: Japan